The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Evaluating the potential of aspirin in preventing recurrence in colorectal cancer
Anna Martling, MD, PhD, Karolinska Institutet, Stockholm, Sweden, chronicles the historical use of aspirin in medicine and previous observations during cardiovascular studies which alluded to aspirin’s role in the prevention of colorectal cancer reoccurrence. Randomized controlled trials have shown that aspirin decrease both the number and size of bowel polyps. Additionally, retrospective research indicates the potential of aspirin for lowering colorectal cancer reoccurrence risk. The ALASCCA trial (NCT02647099) investigates aspirin’s link to the PIK3CA genetic biomarker as a predictive factor in treating colorectal cancer. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
